RESEARCH PROFILE
GLOW
GHK-Cu + BPC-157 + TB-500 • Skin & Tissue Remodeling Research Blend
GLOW is a research blend combining GHK-Cu, BPC-157, and TB-500 within a single research framework focused on skin biology, extracellular-matrix remodeling, tissue repair, cell migration, and connective-tissue research.
The rationale combines the tissue-repair research surrounding BPC-157 and TB-500 with the skin and matrix-remodeling research associated with GHK-Cu.
INVESTIGATIONAL BLEND • NOT FDA APPROVED • COMBINATION NOT CLINICALLY VALIDATED
GLOW AT A GLANCE
Category
Skin, tissue repair, and regenerative research blend
Components
GHK-Cu + BPC-157 + TB-500
Research Rationale
Potentially complementary tissue-repair and extracellular-matrix pathways
Primary Research Focus
Skin remodeling • Collagen biology • Cell migration • Angiogenesis • Connective tissue
Evidence Base
Compound-level human, animal, and laboratory evidence
Combination Evidence
No published human clinical trial evaluating all three compounds together
Regulatory Status
GLOW is not an FDA-approved drug
IMPORTANT DISTINCTION
GLOW is a research combination, not a clinically validated treatment.
Each component has a different evidence base.
GHK-Cu has meaningful human evidence for topical skin applications.
BPC-157 research remains predominantly preclinical.
TB-500-related research frequently relies on studies involving full-length thymosin beta-4 rather than the shorter TB-500 fragment.
No published human trial identified in the Project source has evaluated GHK-Cu + BPC-157 + TB-500 together as the GLOW blend.
WHAT IS THE GLOW BLEND?
GLOW is the research-community name for combining three compounds:
GHK-Cu
BPC-157
TB-500
The Project profile describes the commonly referenced pre-blended formulation as a 5:1:1 ratio, with GHK-Cu as the dominant component.
The research rationale extends the BPC-157 + TB-500 framework by adding GHK-Cu as a third component associated with skin and extracellular-matrix biology.
GHK-Cu
GHK-Cu is a naturally occurring copper-binding tripeptide.
Research has examined its relationship with:
Collagen synthesis
Elastin biology
Skin remodeling
Extracellular matrix
Gene expression
Wound-repair pathways
BPC-157
BPC-157 is a synthetic 15 amino acid peptide studied primarily in animal and laboratory models.
Research areas include:
Angiogenic signaling
Tendon and ligament biology
Cell migration
Gastrointestinal tissue
Soft-tissue repair
TB-500
TB-500 is associated with a functional region of thymosin beta-4 and is researched in connection with:
Actin dynamics
Cell migration
Angiogenesis
Tissue remodeling
Repair signaling
WHY COMBINE THEM?
The research rationale is complementary biological coverage.
BPC-157 and TB-500 form the tissue-repair foundation, while GHK-Cu adds a research layer centered more heavily on skin quality, collagen, elastin, copper biology, and extracellular-matrix remodeling.
This is a research hypothesis.
It does not establish clinical synergy.
MECHANISM OF ACTION
GLOW combines three compounds that are proposed to influence different but overlapping aspects of tissue biology.
BPC-157 — REPAIR SIGNALING
Preclinical BPC-157 research has explored pathways associated with:
Angiogenesis
Cell migration
VEGF signaling
FAK and ERK pathways
Tendon and connective-tissue repair
Its proposed role within GLOW is primarily related to local tissue-repair signaling.
TB-500 — CELL MIGRATION & ACTIN BIOLOGY
Thymosin beta-4-related research centers heavily on actin, a structural protein essential for cell shape and movement.
Research has examined:
Cell migration
Angiogenesis
Wound repair
Tissue remodeling
Connective-tissue organization
Its proposed role within GLOW is therefore related to repair-cell movement and matrix remodeling.
GHK-Cu — SKIN & MATRIX REMODELING
GHK-Cu introduces a different research emphasis.
Studies have explored its effects on:
Collagen synthesis
Elastin
Glycosaminoglycans
Decorin
Matrix metalloproteinases
Gene expression
GHK-Cu therefore provides the primary skin-quality and extracellular-matrix research component of the blend.
ANTI-INFLAMMATORY PATHWAY OVERLAP
The Project source notes that all three compounds have been associated with anti-inflammatory effects through different experimental pathways.
Combining them creates theoretical pathway overlap.
That overlap has not been clinically demonstrated to produce superior outcomes.
ANTI-FIBROTIC & MATRIX REMODELING INTEREST
TB-500-related and GHK-Cu research has explored connective-tissue organization and extracellular-matrix remodeling.
This contributes to interest in GLOW for research involving scar and tissue-quality biology.
IMPORTANT MECHANISM LIMITATION
A plausible combination of mechanisms does not establish clinical effectiveness.
No published human trial has established that GHK-Cu + BPC-157 + TB-500 together improve skin, wound healing, connective-tissue recovery, or other clinical outcomes.
WHAT THE RESEARCH SHOWS
GLOW COMBINATION EVIDENCE
The most important evidence limitation is straightforward:
No published human clinical trial identified in the Project source has evaluated GHK-Cu + BPC-157 + TB-500 together as GLOW.
The evidence must therefore be evaluated at the individual-compound level.
GHK-Cu EVIDENCE
GHK-Cu has the strongest direct human evidence of the three components for topical skin-related endpoints.
Human cosmetic research has examined outcomes involving:
Collagen density
Skin thickness
Fine lines
Skin laxity
Skin appearance
Your Project source also cites broader laboratory and preclinical research involving gene expression, wound healing, and extracellular-matrix remodeling.
However, topical GHK-Cu evidence should not automatically be transferred to injectable GHK-Cu or the injectable GLOW blend.
BPC-157 EVIDENCE
BPC-157 research remains primarily preclinical.
Animal and laboratory studies have investigated:
Tendon healing
Ligament repair
Musculoskeletal soft tissue
Cell migration
Angiogenic signaling
Gastrointestinal tissue
The Project source references a systematic review concluding that the orthopedic literature remains overwhelmingly preclinical.
TB-500 / THYMOSIN BETA-4 EVIDENCE
Human research exists for full-length thymosin beta-4, including Phase I safety studies.
Animal and laboratory research has investigated:
Cell migration
Angiogenesis
Cardiac repair
Wound healing
Connective-tissue remodeling
However, full-length thymosin beta-4 and the TB-500 fragment should not be treated as interchangeable.
SKIN & COLLAGEN RESEARCH
GHK-Cu provides the strongest research rationale for GLOW's skin-focused positioning.
Human topical studies support investigation of GHK-Cu in collagen and skin-remodeling contexts.
But there is no human trial showing that the three-compound injectable GLOW blend improves skin quality.
SOFT-TISSUE RESEARCH
BPC-157 and TB-500-related literature creates a preclinical rationale for investigating:
Tendon biology
Ligament biology
Wound repair
Cell migration
Soft-tissue remodeling
These findings do not establish human therapeutic effectiveness.
IMPORTANT EVIDENCE LIMITATION
GLOW combines three separate evidence bases.
Those evidence bases cannot simply be added together and treated as evidence for the blend.
There is no published human evidence establishing that GLOW:
Accelerates injury recovery
Improves tendon or ligament healing
Reverses skin aging
Improves scars
Increases collagen systemically
Produces superior results to the individual compounds
The proposed benefits remain compound-derived research hypotheses.
SAFETY & RESEARCH CONSIDERATIONS
There is no established human safety profile for the GLOW combination.
Each component introduces its own uncertainties, and combining three compounds creates additional interaction and product-quality considerations.
BPC-157
Human safety information remains limited.
The Project source notes that BPC-157 has not produced a lethal dose in animal toxicity research, but this does not establish human safety.
TB-500
Direct human safety evidence for the TB-500 fragment is limited.
Human Phase I data involving full-length thymosin beta-4 reported no serious adverse events in the cited study, but those findings cannot automatically be transferred to TB-500.
GHK-Cu
GHK-Cu has a history of topical cosmetic use, but injectable exposure has a much weaker human safety database.
COPPER ACCUMULATION
GHK-Cu introduces systemic copper exposure.
The Project profile identifies repeated high exposure as a theoretical concern for copper accumulation.
Particular caution is relevant in people with:
Wilson's disease
Other copper-handling disorders
Significant liver disease
ANGIOGENIC SIGNALING
BPC-157 and TB-500-related biology both involve angiogenic pathways.
Angiogenesis is important for normal repair but can also participate in tumor biology.
The Project profile therefore identifies active cancer or significant cancer history as a theoretical concern.
This does not establish that GLOW causes cancer.
THREE-COMPOUND COMPLEXITY
Every additional compound introduces another opportunity for:
Unexpected interactions
Dose error
Contamination
Mislabeling
Stability problems
Product-quality variation
No clinical trial has characterized the safety of running all three compounds together.
REPORTED EFFECTS
The Project profile notes community-reported effects including:
Injection-site redness or swelling
Short-term fatigue during some TB-500-related protocols
Occasional mild headache
Metallic or warming sensations associated with GHK-Cu
These are community reports rather than controlled clinical adverse-event data.
PREGNANCY & BREASTFEEDING
The Project source identifies insufficient human safety data for the combination during pregnancy or breastfeeding.
REGULATORY CONTEXT
GLOW IS NOT FDA APPROVED
GLOW is not an FDA-approved drug or therapeutic combination.
Pre-blending the compounds does not alter the regulatory status of the individual ingredients.
BPC-157
BPC-157 is not FDA approved.
Your Project source also identifies anti-doping restrictions applicable to BPC-157.
TB-500
TB-500 is not FDA approved as a finished therapeutic drug.
Research involving full-length thymosin beta-4 does not create approval for TB-500.
GHK-Cu
GHK-Cu is used in topical cosmetic contexts.
That does not constitute FDA approval of injectable GHK-Cu as a therapeutic drug.
COMPOUNDING CONTEXT
Your Project profile documents evolving U.S. compounding-related regulatory treatment involving the individual components.
Those regulatory processes can change and should not be interpreted as clinical approval.
ANTI-DOPING STATUS
Your Project source identifies BPC-157 and TB-500-related substances as prohibited for athletes under WADA rules.
The presence of those compounds makes GLOW inappropriate to characterize as compatible with drug-tested competition.
IMPORTANT REGULATORY DISTINCTION
A research blend is not an approved combination drug.
Compounding status is not FDA approval.
Cosmetic use of GHK-Cu is not approval of injectable GHK-Cu.
Clinical or preclinical evidence for individual ingredients does not create regulatory approval for GLOW.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
GLOW 70 MG
Laboratory
Optiq Health Labs
Sample Name
glow 70mg
Lot
ld07092026-4
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only
Report Date
September 18, 2026
Reported Net Content
GHK-Cu: 50.17 mg/vial
BPC-157: 10.27 mg/vial
TB-500: 10.36 mg/vial
Total reported peptide content: 70.80 mg/vial
Reported Purity
99.2%
Identity
GHK-Cu + BPC-157 + TB-500
LC-MS Confirmation • Tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth COAs-2(2)
IMPORTANT PRODUCT MATCHING NOTE
This analytical report is specifically for the sample identified as “glow 70mg.”
The current Project inventory has separately referenced GLOW 80 mg.
Because Croix requires the product and strength to match the laboratory report, this 70 mg COA should not be represented as analytical verification of an 80 mg GLOW product unless the inventory designation is corrected or a matching 80 mg laboratory report is obtained.
IMPORTANT COA LIMITATION
Analytical results apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
BPC-157 RESEARCH
Vanežić N, et al.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Review of the predominantly preclinical BPC-157 musculoskeletal evidence base.
Sikiric P, et al.
Research examining the pleiotropic biological activity of BPC-157.
Gwyer D, et al.
Research examining BPC-157 in musculoskeletal soft-tissue healing.
THYMOSIN BETA-4 RESEARCH
Ruff D, et al.
A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta-4 in healthy volunteers.
Annals of the New York Academy of Sciences. 2010.
Human Phase I research involving full-length thymosin beta-4.
Bock-Marquette I, et al.
Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.
Nature. 2004.
Preclinical cell-migration and repair research.
Smart N, et al.
Research examining thymosin beta-4, progenitor-cell mobilization, and neovascularization.
Philp D, et al.
Research examining thymosin beta-4 in angiogenesis and wound-healing biology.
Ehrlich HP, Hazard SW.
Research examining thymosin beta-4 and connective-tissue organization.
GHK-Cu RESEARCH
Pickart L, Margolina A.
A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
International Journal of Molecular Sciences. 2018.
Review of GHK-Cu, gene expression, skin biology, and regenerative pathways.
Pickart L, Vasquez-Soltero JM, Margolina A.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.
BioMed Research International. 2015.
Review of GHK-Cu and skin-regeneration biology.
Maquart FX, et al.
Research examining stimulation of collagen synthesis by the GHK-Cu complex.
REGULATORY REFERENCES
U.S. Food & Drug Administration
503A bulk drug substance and compounding-related materials relevant to the individual GLOW components.
World Anti-Doping Agency
Current Prohibited List.
EVIDENCE NOTE
These references establish compound-level research context.
They do not establish the clinical efficacy or safety of the three-compound GLOW blend.
No published human clinical trial cited in the Project source has evaluated BPC-157 + TB-500 + GHK-Cu together.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish GLOW as safe or effective for personal use.
GLOW combines GHK-Cu, BPC-157, and TB-500 within a research framework involving skin biology, extracellular-matrix remodeling, cell migration, angiogenesis, and tissue-repair pathways.
The individual compounds have substantially different evidence bases. Human evidence is strongest for topical GHK-Cu, while BPC-157 and TB-500-related regenerative claims rely heavily on animal, laboratory, mechanistic, or parent-peptide research.
GLOW itself is not FDA approved, and no published human clinical trial identified in the Project source has established the safety, efficacy, or superiority of the three-compound combination.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.
← BACK TO REPAIR, SKIN & INFLAMMATORY RESEARCH